Involvement of MAPK pathway in hypoxia-induced up-regulation of urokinase plasminogen activator receptor in a human prostatic cancer cell line, PC3MLN4.
- Author:
Kyung Hee LEE
1
;
Eun Young CHOI
;
Myung Soo HYUN
;
Jae Ryong KIM
Author Information
1. Department of Hemato-Oncology, College of Medicine, Yeungnam University, Daegu 705-717, Korea. lkhee@med.yu.ac.kr
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
HGF;
hypoxia;
MAPK;
metastasis;
uPAR
- MeSH:
Animals;
Anoxia/*metabolism;
Cell Line, Tumor;
Cell Proliferation;
Humans;
MAP Kinase Signaling System/*physiology;
Male;
Mitogen-Activated Protein Kinases/*metabolism;
Phosphorylation;
Prostatic Neoplasms/*metabolism/pathology;
Protein Kinase Inhibitors/metabolism;
Receptors, Cell Surface/genetics/*metabolism;
Research Support, Non-U.S. Gov't;
*Up-Regulation
- From:Experimental & Molecular Medicine
2004;36(1):57-64
- CountryRepublic of Korea
- Language:English
-
Abstract:
Clinical studies have shown that tumor hypoxia is associated with invasive growth and metastasis and may be an important prognostic factor adversely influencing survival in patients with tumors. To investigate the mechanisms involved in hypoxia-induced invasive growth and metastasis, hypoxia-mediated urokinase plasmalogen activator receptor (uPAR) expression, cellular invasiveness, and mitogen activated protein kinase (MAPK) activation were measured in a prostate cancer cell line, PC3MLN4. The levels of uPAR expression and cellular invasiveness were increased in hypoxic cells. Hypoxia-induced cellular invasiveness was blocked by an anti-uPAR monoclonal antibody. Phosphorylations of ERK and p38 kinases were also more extensive in hypoxic cells than in normoxic cells. Hypoxia-induced uPAR up-regulation was inhibited by pre-treatments with a specific inhibitor of MEK, PD98059 and a specific inhibitor of p38 MAP kinase, SB203580. Cell growth also increased in hypoxic cells. From these results, hypoxia increased tumor cell invasion by up-regulating uPAR expression, which might be mediated through ERK and p38 kinase signaling pathways in PC3MLN4 prostate cancer cell line.
